When his PSA score spiked, prostate surgery loomed, but NIH offered another way

Daniel Peck/Peck Studios - For Jim Cassell and his wife, Marilyn Fenichel, a warning about prostate cancer left them feeling “as though we’d fallen down a medical rabbit hole.”

A few weeks before our long-awaited trip to Italy in 2011, my husband, Jim, received a disconcerting phone call about one of the results of his annual physical. Jim’s PSA, a blood test that screens for early-stage prostate cancer, had been rising over the past couple of years. His internist was becoming concerned, and he suggested that Jim get another PSA when he returned from Europe.

I didn’t think much about this while we were away. I assumed my healthy, youthful husband, in his early 60s, couldn’t possibly be one of the almost 2.5 million American men living with prostate cancer. So I was surprised when the PSA test Jim had after our trip showed a continued increase. With this latest information, Jim’s internist thought it was time for him to see a urologist.

Graphic

Thanks in part to earlier diagnoses and advances in treatment, the chances of surviving some of the most common types of cancer have increased.
Click Here to View Full Graphic Story

Thanks in part to earlier diagnoses and advances in treatment, the chances of surviving some of the most common types of cancer have increased.

More health and science news

Push is on to promote health law

Push is on to promote health law

A coalition with ties to the White House launched a multimillion-dollar effort to sign up the uninsured.

White House, NASA want help hunting asteroids

White House, NASA want help hunting asteroids

On Tuesday, they will announce a “Grand Challenge” to find killer space rocks.

Susan G. Komen names CEO to replace founder Nancy Brinker

After the Planned Parenthood funding controversy, Komen chooses health policy leader Judith Salerno.

We made an appointment and unknowingly entered into the contentious arena of how to respond to potentially worrisome prostate cancer tests.

Originally used to track the progress of cancer treatment, the PSA test is now widely used to detect possible signs of early-stage prostate cancer. But it is an imperfect tool — so imperfect, in fact, that recently the U.S. Preventive Services Task Force, which is charged with tracking medical practices and treatments, said the test should no longer be part of routine standard of care.The test does more harm, through unnecessary surgery, than good, the group said. The recommendation, which reversed the task force’s previous position, has been extremely controversial, with many urologists, cancer doctors and prostate cancer survivors decrying it, saying the PSA test had saved lives.

All of this, though, was well in the future. For now, all we knew was that his PSA was elevated. The question was what to do. In trying to answer that, we felt as though we’d fallen down a medical rabbit hole.

A puzzling about-face

The medical consensus has been that if the PSA number is above 4.0 and this is confirmed in a second test, a biopsy should be done. Clinicians also get concerned when the PSA number rises too quickly; a two-point rise — say, from 1.5 to 3.5 over a two- or three-year period — can be a red flag. My husband fell into the latter category. But as the urologist took great pains to tell us, the rise could mean nothing. Some men who have prostate cancer fall below 4.0, and others whose number is above 4.0 do not have cancer.

We found the doctor’s realistic assessment of the PSA reassuring, and we were sure he wouldn’t recommend a biopsy unless Jim’s third PSA, done through the urologist’s own lab, showed an increase. When the result came back, Jim’s PSA number had stabilized, but the doctor nonetheless recommended a biopsy. When Jim asked why, the doctor expressed concern about the PSA numbers and thought that a biopsy was warranted.

We were puzzled by what seemed to be an about-face: First, the PSA was not to be trusted, then it was the reason to perform a painful, invasive procedure. But the doctor seemed sure, so Jim went ahead with the biopsy the next week.

When the results came back, the doctor explained them by laying out a diagram of Jim’s prostate. He pointed to a bar, with a small area shaded in, on the lower-right segment, or core, which he said indicated the presence of a small, early-stage tumor. The doctor said the virulence of the tumor, measured by the Gleason score, was 6, which meant it was slow-growing. Two other cores had spots that looked suspicious, meaning they might develop into cancer down the road.

Loading...

Comments

Add your comment
 
Read what others are saying About Badges